Squarepoint
ADMA icon

Squarepoint’s ADMA Biologics ADMA Stock Holding History

Squarepoint’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,500
Closed -$486K – 4436
2025
Q1 		$486K Buy
+24,500
New +$424K ﹤0.01% 3324

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Squarepoint's ADMA Position: Q2 2026 in Review

Squarepoint increased its ADMA Biologics (ADMA) stake by 330% in Q2 2026, buying an estimated $2.5M and bringing the position to 357,503 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2012.

Squarepoint first reported a position in ADMA in Q2 2018 and has held it in 25 quarters since. The position peaked at $7.1M in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Squarepoint held 357,503 shares of ADMA Biologics worth $2.99M as of Q2 2026.
  • Squarepoint bought 274,277 ADMA Biologics shares in Q2 2026, an estimated $2.5M.
  • ADMA Biologics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2012 holding.
  • Squarepoint first reported a position in ADMA Biologics in Q2 2018 and has held it in 25 quarters since.
  • Squarepoint's ADMA Biologics position peaked at $7.1M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.